Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 94
Filtrar
1.
Nutr. clín. diet. hosp ; 44(1): 143-155, Feb. 2024. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-231313

RESUMO

Introducción: La calidad de vida del adulto mayor se deteriora a un ritmo acelerado por la presencia del cáncer de estómago, debido a los cambios internos o externos sufridos durante el proceso de esta enfermedad. Determinar el estado nutricional en adultos mayores con cáncer de estómago en la mejora de la calidad de vida en los pacientes que acude al Hospital de Guayaquil Dr. Abel Gilber Potón 2) Materiales y métodos: la implementada fue descriptiva, correlacional, con un diseño cualitativo, y semicuantitativo. La muestra está conformada por 70 pacientes del área de oncología del hospital entre las edades de 65 a 90 años. 3) Resultados: se encontró que el rango de edad es frecuente de 65 ± 70 años en un 41%; con respecto al sexo masculino predomina el 60%; en la etnia mestiza prevalece el 77%; en cuanto al índice de masa corporal se encuentra el 61% de bajo peso; el estadio B del cáncer de estómago según la valoración global subjetiva se presenta con mayor frecuencia; en base a la clasificación por estadios, el estadio IV es del 41,4%; el tratamiento sugerido fue de gastrectomía total en un 52,8%; cabe destacar que en la calidad de vida se identificó relación con el estado nutricional moderado en: dificultad para concentrarse 44%; depresión 64%; y pérdida de memoria 55%; dolor 56%: pérdida de apetito 64%; náuseas 64%; y diarrea 54%. 4) Conclusión: Se debe tener en cuenta que el cáncer gástrico es una neoplasia que genera una alta mortalidad y afecta la calidad de vida por lo cual se debe establecer una adecuada Dietoerapia de acuerdo con los requerimientos individuales del paciente considerando también las preferencias, la cultura y los efectos secundarios como las alteraciones organolépticas que se presentan por el tratamiento, además es importante el apoyo psicosocial del entorno.(AU)


Introduction: The quality of life of the elderly deterioratesat an accelerated rate due to the presence of stomach cancer,due to the internal or external changes suffered during theprocess of this disease. Objective: Determine the relationship between nutritionalstatus and quality of life in older adults with stomach cancerwho attend the Guayaquil hospital, Dr. Abel Gilbert Pontón,Guayas, January to September 2022.Methods: descriptive, correlational, qualitative and semi-quantitative study using the Screening carried out by Detskyin 1987, which measures nutritional risk, based on aspects ofthe clinical and physical history. To analyze the informationcollected, the Microsoft Excel 2016 and IBM SPSS Statistic Vprograms were used. 22. Kendall’s Tau C correlation test andKendall’s Tau B test (non-parametric measures) were appliedin order to establish conclusions. and validate hypotheses re-garding the relationship between VGS, stages and treatmentwith the nutritional status of patients suffering from gastricAC. The sample is taken from the population treated in theoutpatient clinic of the Guayaquil Dr. Abel Gilbert PontónHospital with a sample of 70 older adults with stomach can-cer from 65 to 90 years old.Results: When evaluating the nutritional status of olderadults with cancer through the subjective global assessment,it was found that 54% had stage B or moderately malnour-ished. Approximately 30% are found in stage C with malnu-trition, and 16% in normal stage A. When relating the nutri-tional status through the subjective global assessment andthe quality of life of the elderly with stomach cancer in refer-ence to the relationship nutritional status with the subjectiveglobal assessment, patient stages and patient treatment, allare statistically significant, with a medium negative correla-tion (tau = -0.436; p value.Conclusion: It must be taken into account that gastriccancer is a neoplasm that generates high mortality and af-fects the quality of life...(AU)


Assuntos
Humanos , Masculino , Feminino , Idoso , Idoso de 80 Anos ou mais , Gatos , Qualidade de Vida , Estado Nutricional , Neoplasias Gástricas , Fatores de Risco , Equador , Ciências da Nutrição , Epidemiologia Descritiva , Pesquisa Qualitativa
2.
Pharm. pract. (Granada, Internet) ; 21(4)oct.- dec. 2023. tab
Artigo em Inglês | IBECS | ID: ibc-229972

RESUMO

Background: The development of clinical pharmacy practice for humans and animals in the recent years has resulted in new goals and challenges for pharmacists that work to improve patient care, preventing medication related problems and optimizing resources. Currently, in Spain, there are so many dogs’ and cats’ vaccines from different manufacturers, with different microorganisms’ combination which are not readily identifiable. This fact makes us wonder if they are all necessary and/or convenient, and if they meet the criteria of the international guidelines. Objective: It aimed to examine the current situation of vaccination in dogs and cats in Spain, as well as if available vaccines are suitable, or if the technical data sheets match with the recommendations of consensus guides. Methods: All available vaccines in Spain were counted, evaluated and classified by using the search engine CIMAvet, into monovalent or combined and suitable or unsuitable according to their composition and vaccination schedule with guidelines WSAVA and COLAVAC. Results: As a result, we found 15 vaccines for dogs and 7 for cats, when attending to its composition. However, it gives rise to 46 vaccines for dogs and 14 for cats, if we regarded to the different manufacturers. The 69.6% of dogs’ and 57.1% of cats’ vaccines were considered unsuitable. Resulting as optimal combinations of microorganisms: Bordetella+Parainfluenza, Distemper+Adenovirus+Parvovirus, Leptospira alone and Rabies alone for dogs and Calicivirus+Herpes virus+Panleukopenia, Leukemia alone and Rabies alone for cats. Besides, it was observed that vaccines data sheet don´t meet with international schedule in percentages of 69.6% and 64.3% respectively. Conclusion: Only 28.6% of dogs’ and 42.9% of cats’ vaccines in Spain, are considered suitable, and 30.4% of dogs’ and 35.7% of cats’ vaccines data sheets fully agree with guidelines (AU)


Assuntos
Animais , Gatos , Cães , Cobertura Vacinal , Assistência Farmacêutica , Vacinação/veterinária , Espanha
3.
Rev. iberoam. micol ; 39(3-4): 61-67, julio-diciembre 2022. ilus, tab
Artigo em Inglês | IBECS | ID: ibc-215458

RESUMO

The domestic cat is the most susceptible host to Sporothrix infection, developing severe clinical forms. Few effective antifungal agents are available for treating feline sporotrichosis, and cases of treatment failure are common. Treatment success depends on cat health status, therapy-related factors, as well as social/economic issues, but it is mainly contingent upon the host–fungus interaction. The owner's adherence is critical and should be reinforced throughout the treatment to increase the chances of a successful outcome. The antifungal agents described for feline sporotrichosis are most often used in monotherapy regimens. Due to cases in which the treatment with itraconazole failed, the use of antifungal agents in combination should be considered to achieve synergy. The combination of itraconazole and potassium iodide represents an important option for the treatment of naïve cats presenting multiple cutaneous lesions, nasal mucosal lesions and/or respiratory signs, as well as for refractory cases. However, the therapeutic options for unsuccessfully treated cases are scarce. Therefore new options are needed, even more taking into account that there are many in vitro potential molecules not available for use in cats yet. More studies are necessary to correlate in vitro antifungal susceptibility tests results and the outcome of cats treated due to sporotrichosis. This review will briefly discuss both the antifungal drugs and treatment protocols used in cats with sporotrichosis, as well as the determinants of treatment failure. (AU)


El gato doméstico es el huésped más susceptible a la infección por Sporothrix, llegando a desarrollar formas clínicas graves. Hay pocos agentes antimicóticos efectivos disponibles para tratar la esporotricosis felina, y los casos de fracaso terapéutico son habituales. El éxito del tratamiento depende del estado de salud del gato, los factores relacionados con la terapia y los problemas sociales/económicos, pero se asocia principalmente con la interacción huésped-hongo. El cumplimiento del tratamiento por parte del propietario es fundamental y debe reforzarse durante todo el proceso para aumentar las posibilidades de éxito. Los agentes antimicóticos descritos para la esporotricosis felina se usan con mayor frecuencia en monoterapia. Debido a los casos de fallo terapéutico en el tratamiento con itraconazol se debe considerar el uso combinado de agentes antifúngicos en sinergia. La combinación de itraconazol y yoduro de potasio es una buena opción en el caso de gatos no tratados previamente y con múltiples lesiones cutáneas, en la mucosa nasal y/o con signos respiratorios, así como para casos refractarios. Sin embargo, las opciones terapéuticas para la mayoría de los casos que fracasan son escasas. Por tanto, son necesarias nuevas opciones terapéuticas, más aún cuando existen muchas moléculas potenciales in vitro, no disponibles de momento para su uso en gatos. Son necesarios más estudios que correlacionen los resultados de las pruebas de sensibilidad in vitro a los antifúngicos con aquellos del tratamiento de gatos con esporotricosis. Esta revisión discutirá brevemente los fármacos antimicóticos y los protocolos terapéuticos utilizados para tratar gatos con esporotricosis, así como los factores determinantes del fracaso del tratamiento. (AU)


Assuntos
Humanos , Animais , Esporotricose , Terapêutica , Sporothrix , Gatos
6.
Artigo em Inglês | IBECS | ID: ibc-203903

RESUMO

Objective: We aimed to evaluate the efficacy of and immunologic changes caused by subcutaneous immunotherapy (SCIT) in patients with allergy to cat and dog.Methods: The study population comprised patients with rhinitis and/or asthma and allergy to cat or dog from a previous safety study. All patients had specific IgE to cat and/or dog. The SCIT maintenance dose was administered using an infusion pump over a single 4-hour session, followed by monthly administration over 6 months. Data were gathered on clinical outcomes, pulmonary function, FeNO, rhinitis and asthma symptoms, quality of life (QOL), and scores for the Asthma Control Test and symptom visual analog scale were recorded at baseline and then at 1, 3, and 6 months. Specific IgE and IgG antibody responses to cat and dog allergens were determined.Results: The study population comprised 61 patients with a mean age of 35.6 (9.7) years, of whom 40 underwent SCIT for at allergy. A significant improvement was observed in rhinitis and asthma symptoms and in QOL, use of medication, visual analog scale score, and Asthma Control Test score at 1 month; these improvements persisted at month 6. The clinical improvement with cat extract was significantly more marked than with dog extract. Nearly half of the patients (49.09%) had an increase of >0.9 in the ESPRINT-15 QOL in allergic rhinitis questionnaire, and 58.18% had an increase of >0.5 in the Asthma Quality of Life Questionnaire score at month 6. Both differences represent the minimal clinical important difference. A significant increase was observed in specific IgG and IgE to different allergens at 3 and/or 6 months.Conclusions: Ultrarush SCIT with cat and dog extracts has substantial clinical value for many patients (AU)


Objetivo: Nuestro objetivo fue evaluar la eficacia y los cambios inmunológicos causados por la inmunoterapia subcutánea (SCIT) enpacientes con alergia a perro y gato.Métodos: Se incluyeron pacientes que presentaban rinitis y/o asma con alergia al gato o al perro de un estudio de seguridad previo. Todostenían IgE específica para gato y/o perro. Usando una bomba de infusión (IP), la dosis de mantenimiento de SCIT se administró duranteuna sesión de 4 horas, seguida de la administración mensual durante 6 meses. Se recopilaron datos de función pulmonar, FeNO, síntomasde rinitis y asma, calidad de vida (QoL), control del asma (ACT) y escala analógica visual de síntomas (VAS) al inicio y a los 1, 3 y 6 meses.Se determinaron las respuestas específicas de anticuerpos IgE e IgG a diferentes alérgenos de perro y gato.Resultados: Se incluyeron 61 pacientes con una edad media de 35,6 ± 9,7 años, 40 de los cuales se sometieron a SCIT de gato. Seobservó una mejora significativa en los síntomas de rinitis y asma, calidad de vida, el uso de medicamentos, VAS y ACT en el primer mes.Estas mejorías se mantuvieron en el mes 6. La mejoría clínica con el extracto de gato fue significativamente mayor que con el de perro.Se observó un aumento de >0,9 en ESPRINT-15 en el 49,09% de los pacientes, y el 58,18% mostró un aumento de >0,5 en AQLQ enel mes 6, ambas diferencias indican la mínima diferencia importante. Se observó un aumento significativo en IgG e IgE específicas adiferentes alérgenos a los 3 y/o 6 meses.Conclusiones: La SCIT ultrarápida con extractos de perro y gato induce una mejoría clínica relevante rápida y mantenida en muchos pacientes (AU)


Assuntos
Humanos , Animais , Masculino , Feminino , Gatos , Cães , Asma , Rinite Alérgica , Alérgenos , Dessensibilização Imunológica , Imunoglobulina E , Imunoglobulina G , Injeções Subcutâneas , Extratos Vegetais , Qualidade de Vida
7.
J. investig. allergol. clin. immunol ; 32(5): 383-392, 2022. ilus, graf
Artigo em Inglês | IBECS | ID: ibc-212734

RESUMO

Background: Immediate and delayed-type hypersensitivity reactions to pet-borne allergens are common in atopic diseases. In atopic dermatitis (AD), controversy surrounds the contribution to the disease of cross-reactivity to self-proteins. Human cystatin A and the cat allergen Fel d 3 belong to the cystatins, an evolutionary conserved protein family. The objective of the present study was to assess crossreactivity between mammalian cystatins and to analyze T-cell responses to cystatin in AD patients sensitized to pet dander. Methods: cDNA coding for dog cystatin was cloned from dog skin. Sera from 245 patients with IgE-mediated sensitization to cat and dog dander were tested for IgE binding to recombinantly expressed feline, canine, and human cystatin. Of these, 141 were also diagnosed with AD. Results: Cystatin-specific IgE was detected in 36 patients (14.7%), of whom 19 were considerably affected by AD. Within the AD patients, 9 had measurable IgE against all 3 cystatins. Cystatin-sensitized AD patients did not differ from non–cystatin-sensitized patients in terms of disease severity, age, or total IgE levels. T-cell cytokine measurements showed elevated IL-4 levels after stimulation with feline and human cystatin. Conclusion: The humoral response suggests that in addition to Fel d 3, the homologous protein from dog might play a role in allergy. Furthermore, human cystatin appears to be capable of driving a type 2 immune response in sensitized AD patients and may therefore be considered a so-called autoallergen, as proposed for other evolutionary conserved proteins. (AU)


Antecedentes: Las reacciones de hipersensibilidad de tipo inmediato y retardado a los alérgenos que están en las mascotas son comunes en las enfermedades atópicas. En este estudio, en pacientes con dermatitis atopica (DA), se analiza la reactividad cruzada con las autoproteínas y su contribución a la enfermedad. Tanto la cistatina A humana como el alérgeno felino Fel d 3 pertenecen a la familia de las cistatinas, una familia de proteínas conservadas evolutivamente. El objetivo del presente estudio fue evaluar la reactividad cruzada entre las cistatinas de mamíferos y analizar la respuestas de las células T a la cistatina en pacientes con DA sensibilizados a la caspa de las mascotas. Métodos: El ADNc que codifica la cistatina de perro se clonó a partir de piel de perro. Se analizaron sueros de 245 pacientes con sensibilización por IgE a la caspa de gato y perro para determinar la unión de IgE a cistatina felina, canina y humana expresada de forma recombinante, respectivamente. De estos 245 pacientes, 141 fueron diagnosticados de DA. Resultados: Se detectó IgE específica frente a cistatina en el 14,7% (36) de los pacientes, de los cuales 19 padecían DA. Dentro de los pacientes con DA, 9 tenían IgE medible contra las tres cistatinas. Los pacientes con DA sensibilizados frente a cistatina no difirieron de los pacientes no sensibilizados con cistatina en términos de gravedad de la enfermedad, edad o niveles totales de IgE. El análisis de citocinas de células T reveló niveles elevados de IL-4 después de la estimulación con cistatina felina y humana. Conclusión: La respuesta humoral sugiere que, además de Fel d 3, la proteína homóloga de perro también podría desempeñar un papel en la alergia. Además, la cistatina humana parece ser capaz de promover una respuesta inmune de tipo 2 en pacientes con DA sensibilizados y, por lo tanto, puede considerarse un autoalérgeno, como se ha propuesto para otras proteínas conservadas evolutivamente. (AU)


Assuntos
Humanos , Animais , Gatos , Cães , Dermatite Atópica/etiologia , Animais de Estimação , Apresentação Cruzada , Cistatinas/imunologia , Linfócitos T/imunologia , Dermatite Atópica/imunologia , Ensaio de Imunoadsorção Enzimática , Eletroforese em Gel de Poliacrilamida
8.
J. negat. no posit. results ; 6(12): 1446-1460, Dic. 2021. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-224365

RESUMO

Objetivos: Identificar la seropositividad y seronegatividad de IgM para Toxoplasmosis, así como los posibles factores de riesgo asociados a las mismas, en mujeres en edad reproductiva de Tampico, Madero y Altamira, con la finalidad de aportar nueva información contextualizada que permita llevar a cabo acciones de prevención. Material y Métodos: Se determinó la seropositividad y seronegatividad para IgM anti-Toxoplasma gondii mediante muestras de punción dactilar en casetes de TORCH en 50 pacientes femeninas en edad reproductiva de 22 a 35 años de edad de Tampico, Madero y Altamira. Así como su relación con los posibles factores de riesgo asociados a Toxoplasmosis mediante un cuestionario elaborado por los investigadores. Resultados: La seronegatividad y seropositividad de tipo IgM anti-Toxoplasma gondii en 50 mujeres en edad reproductiva de 22 a 35 años de edad en la zona conurbada fue de 100% y 0% respectivamente. Los factores de riesgo asociados a Toxoplasmosis que se presentaron con mayor frecuencia en la población seronegativa fueron el consumo de carne mal cocinada (36%) y la convivencia con gatos (26%).Discusión y Conclusiones: Se encontró una seropositividad nula a IgM anti-Toxoplasma gondii, y una baja frecuencia de exposición y/o contacto con los posibles factores de riesgo asociados a Toxoplasmosis. Se sugiere estudiar poblaciones que acudan al sector público de salud y realizar la búsqueda de anticuerpos anti-Toxoplasma gondii mediante la determinación de ambas pruebas: IgM e IgG.(AU)


Objectives: Identify the seropositivity and seronegativity of IgM for Toxoplasmosis, as well as the possible risk factors associated with them, in women of reproductive age from Tampico, Madero and Altamira, in order to provide new contextualized information that allows carrying out prevention actions. Material and Methods: The seropositivity and seronegativity for IgM anti-Toxoplasma gondii were determined by the fingerprint puncture samples in TORCH cassettes in 50 female patients of reproductive age (22-35 years) from Tampico, Madero and Altamira. As well as its relationship with the possible risk factors associated with Toxoplasmosis through a questionnaire prepared by researchers. Results: Seronegativity and seropositivity of IgM anti-Toxoplasma gondii in 50 women of reproductive age between 22 and 35 years old in the metropolitan area was 100% and 0% respectively. The risk factors associated to Toxoplasmosis with higher frequency in the seronegative population were the consumption of poorly cooked meat (36%) and the coexistence with cats (26%). Discussion and Conclusions: A nule seropositivity to anti-Toxoplasma Gondii IgM and a low frequency of exposure and/or contact with possible risk factors associated with Toxoplasmosis was found.(AU)


Assuntos
Humanos , Feminino , Adulto , Fatores de Risco , Imunoglobulina M , Toxoplasmose , Complicações na Gravidez , Anticorpos , Zoonoses , Inquéritos e Questionários , Carne , Gatos , Estudos Soroepidemiológicos , México
9.
Allergol. immunopatol ; 49(4): 155-161, jul. 2021. tab, graf
Artigo em Inglês | IBECS | ID: ibc-214296

RESUMO

Introduction and objectives: With increasing pet allergies among pediatric patients, the need for precise environmental care is increasing. We investigated the clinical, immunological, and environmental characteristics of pediatric patients sensitized to a dog to evaluate the cross-antigenicity of canine lipocalin Can f 1 with feline lipocalin Fel d 1 and Syrian hamster extract. Materials and methods: The protein fractions of the processed and commercial Syrian hamster extracts were compared using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). An enzyme-linked immunosorbent assay (ELISA) inhibition test was performed on Can f 1, Fel d 1, and processed Syrian hamster extract, and the antigen-specific immunoglobulin E (IgE)-binding capacity for each antigen was analyzed using serum samples from patients. Results: Twelve of 19 patients with a median age of 40.5 months were symptomatic when exposed to dogs. Eleven (91.7%) patients showed a positive IgE response to Can f 1. Two patients were positive for Fel d 1-specific IgE antibody, and one was positive for hamster-specific IgE antibody. SDS-PAGE confirmed the presence of different patterns of protein bands between the commercial and processed hamster extracts. There was no cross-antigenicity among Can f 1, Fel d 1, and processed Syrian hamster extract. Conclusions: Since the standard commercial hamster extract did not contain Syrian hamster antigens that were diverse enough, caution should be taken when using it. In children allergic to cats and dogs, sensitization to isolated Can f 1 or Fel d 1 is unlikely to cause cross-reactivity to Syrian hamster hair and epithelium (AU)


Assuntos
Humanos , Animais , Pré-Escolar , Criança , Gatos , Cães , Cricetinae , Alérgenos/imunologia , Extratos Vegetais , Estudos Retrospectivos , Ensaio de Imunoadsorção Enzimática , Imunoglobulina E , Lipocalinas/imunologia , Apresentação Cruzada , Alérgenos Animais/imunologia
12.
Allergol. immunopatol ; 48(6): 612-618, nov.-dic. 2020.
Artigo em Inglês | IBECS | ID: ibc-199250

RESUMO

BACKGROUND: The chemical modification of allergens with glutaraldehyde improves safety while maintaining clinical efficacy, which permits the administration of higher doses of immunotherapy, reducing the risk of adverse reactions. The aim of this study is to evaluate the immunogenic capacity of a new cat dander polymer by immunizing mice and quantifying immunoglobulins in serum, in comparison with the non-modified allergen. METHODS: The study consists of the immunization of three mice groups with the polymerized and the native extract, together with a negative control group. The immunoglobulin levels in serum have been measured by indirect ELISA. By means of the non-parametric Mann-Whitney U test, it was determined if there were significant differences in the values of specific antibodies between groups. RESULTS: The group immunized with the allergoid showed significantly higher specific IgG and IgG1 values to dander allergens and specific IgG to the major allergen Fel d 1, while there were no significant changes in IgG2a and IgE values. These results could be due to a higher immunization dose. The vaccine formulation was based on the optimal defined dose for clinical efficacy of allergen immunotherapy. CONCLUSIONS: This preclinical study carried out with the present assay has established that the allergoid of cat dander extract, as designed for its optimal use in allergen immunotherapy, produces a higher specific IgG than the native extract, in addition to showing significantly higher specific IgG1 levels, evidencing a greater effectiveness in immunization


No disponible


Assuntos
Animais , Feminino , Gatos , Camundongos , Imunogenicidade da Vacina/imunologia , Dessensibilização Imunológica/métodos , Alérgenos/imunologia , Gatos/imunologia , Hipersensibilidade/prevenção & controle , Imunoglobulinas/sangue , Ensaio de Imunoadsorção Enzimática , Reprodutibilidade dos Testes , Valores de Referência , Avaliação Pré-Clínica de Medicamentos , Glicoproteínas/imunologia , Hipersensibilidade/imunologia
15.
Allergol. immunopatol ; 48(2): 130-136, mar.-abr. 2020. tab
Artigo em Inglês | IBECS | ID: ibc-191815

RESUMO

BACKGROUND: Several studies suggest that early-life exposure to animal allergens constitutes a relevant risk factor for the development of allergic sensitization. OBJECTIVES: The aim of the present study was to determine the role of interleukin-33 in children sensitive to cat allergen with allergic rhinitis and/or asthma. METHODS: The study included 51 children aged 5-18 years, both sexes, allergic to cats. Sensitization to cat allergen was confirmed by skin prick tests or specific IgE. Children were evaluated for the presence of bronchial asthma, atopic dermatitis, allergic rhinitis. A questionnaire evaluating the occurrence of allergic symptoms in children after contact with the cat and dog was performed. Mothers completed a questionnaire regarding cat exposure: during pregnancy and having a cat at home. A blood sample was taken from all children to measure the level of IL-33 in the serum. RESULTS: Keeping a cat in the home, once in the past, or having a cat in the home during the mother's pregnancy, revealed a statistically significant relationship with IL-33 levels in the studied patients. Also, daily contact with a cat during pregnancy affected the level of IL-33. Higher levels of IL-33 were shown in people with hypersensitivity to cat and pollen allergens and cat and other animals. In patients with bronchial asthma higher levels of IL-33 were found than in patients without bronchial asthma. CONCLUSIONS: Increased serum levels of IL-33 is related with keeping cats during pregnancy and in early childhood and can be associated with the development of asthma in children


No disponible


Assuntos
Humanos , Animais , Masculino , Feminino , Criança , Adolescente , Gatos , Interleucina-33/imunologia , Alérgenos/imunologia , Hipersensibilidade/diagnóstico , Gatos/imunologia , Hipersensibilidade/imunologia , Animais de Estimação/imunologia , Rinite/imunologia , Rinite/diagnóstico , Asma/diagnóstico , Asma/imunologia , Inquéritos e Questionários , Modelos Lineares
17.
Allergol. immunopatol ; 48(1): 90-94, ene.-feb. 2020. tab, graf
Artigo em Inglês | IBECS | ID: ibc-186598

RESUMO

Background: Both home and school are important places where children are exposed to various indoor allergens. This study aimed to identify the profile of indoor allergens in schools and its impact on asthma development. Methods: A total of 104 classrooms from 52 schools were selected for dust collection during the fall of 2017. The levels of indoor allergens including dust mite (Der f1, Der p1), cat (Fel d1), cockroach (Bla g1) and mouse (Mus m1) were measured by enzyme linked immunosorbent assay (ELISA). The diagnosis of asthma was made in all students of the selected classes by the allergist. The collected data were analyzed using SPSS version 21.0. Results: Out of 2816 students in the selected classes, 180 students were involved with asthma. Students were mostly exposed to Bla g1 (83.1%), followed by Der f1 (51.5%), Mus m 1 (45.5%), Der p1 (8.9%) and Fel d1 (7.9%) in the dust collected from 101 classrooms. Although levels of all studied allergens in the settled dust of the classrooms were low, there was a relationship between Fel d1 in the classroom dust and development of asthma. Conclusion: This study showed considerable levels of cockroach allergens in schools. Exposure to cat allergen in our schools played an important role in asthma development; further school-based investigations require evaluating the role of classroom allergen on asthma development


No disponible


Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Asma/epidemiologia , Alérgenos/imunologia , Fatores de Risco , Exposição Ambiental , Asma/imunologia , Irã (Geográfico)/epidemiologia , Poluição do Ar em Ambientes Fechados/efeitos adversos , Ácaros/imunologia , Gatos , Ensaio de Imunoadsorção Enzimática , Baratas
18.
J. investig. allergol. clin. immunol ; 30(3): 169-174, 2020. graf
Artigo em Inglês | IBECS | ID: ibc-195168

RESUMO

BACKGROUND: Data on the efficacy of immunotherapy administered to patients with cat or dog allergy are scarce. OBJECTIVE: We aimed to evaluate the safety and efficacy of subcutaneous immunotherapy (SCIT) in patients with allergy to cat and dog dander. METHODS: Consecutive patients with rhinitis and/or asthma related to sensitization to cat or dog dander were included in a pragmatic, real-life, prospective, observational study. All patients had specific IgE to cat, dog, or both. SCIT was administered using an infusion pump over 3 sessions as part of a rush protocol, followed by monthly administration over 12 months. We recorded adverse events, clinical outcomes, pulmonary function, FeNO, symptoms of rhinitis and asthma, quality of life (QoL), Asthma Control Test (ACT) score, and visual analog scale (VAS) score at baseline, 6 months, and 12 months. RESULTS: The study population comprised 66 patients (38 females, 46 allergic to cat and 20 to dog), with ages ranging from 9 to 59 years. During the up-dosing phase, in which the infusion pump was used, 8.1% of doses elicited a systemic reaction and 5.4% caused a local reaction, while 9.3% of doses administered during the maintenance phase (ie, without an infusion pump) induced a systemic reaction. No local reactions were recorded. A significant improvement in FEV1, symptoms of rhinitis and asthma, QoL, use of medication, VAS score, and ACT score was observed at 6 months and continued at 12 months. Clinical improvement with cat extract was significantly better than with dog extract. CONCLUSIONS: High-dose SCIT has substantial clinical value in many cat- and dog-allergic patients


ANTECEDENTES: Hay pocos estudios sobre la eficacia de la inmunoterapia administrada a pacientes con alergia a perro o gato. OBJETIVO: Evaluar la seguridad y la eficacia de la inmunoterapia subcutánea (SCIT) en pacientes con alergia a estos dos animales. MÉTODOS: Se incluyeron pacientes consecutivos con rinitis y/o asma relacionados con la sensibilización al gato o al perro en un estudio observacional prospectivo, pragmático, en vida real. Todos los pacientes tenían IgE específica para gato y/o perro. La SCIT se administró utilizando una bomba de infusión (IP), en 3 sesiones como parte de un protocolo rápido, seguido de la administración mensual durante 12 meses. Se recopilaron datos sobre efectos adversos y resultados clínicos, función pulmonar, FeNO, síntomas de rinitis y asma, calidad de vida (QoL), prueba de control del asma (ACT) y escala analógica visual (VAS) al inicio, a los 6 y 12 meses. RESULTADOS: Se incluyeron 76 pacientes: 38 mujeres, 46 alérgicos a gato y 20 a perro, con edades comprendidas entre los 9 y los 59 años. Durante la fase de administración ascendente, utilizando una IP, el 8,1% de las dosis provocó una reacción sistémica (SR) y el 5,4% causó una reacción local (LR), mientras que el 9,3% de las dosis administradas durante la fase de mantenimiento (es decir, sin IP) desarrolló una SR, y no se registraron LRs. Se observó una mejoría significativa en el FEV1, en los síntomas de rinitis, de asma y en los cuestionarios de la calidad de vida, uso de medicación, VAS y ACT a los 6 meses y continuó a los 12 meses. La mejoría clínica con el extracto de gato fue significativamente mayor que con el perro. CONCLUSIONES: Las dosis altas de SCIT tienen un valor clínico sustancial en muchos pacientes alérgicos a perros y gatos


Assuntos
Humanos , Animais , Masculino , Feminino , Criança , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Gatos , Cães , Dessensibilização Imunológica/métodos , Hipersensibilidade Imediata , Imunoglobulina E/imunologia , Rinite Alérgica/terapia , Asma/terapia , Alérgenos Animais/imunologia , Resultado do Tratamento , Inquéritos e Questionários , Estudos Prospectivos , Qualidade de Vida
19.
Allergol. immunopatol ; 47(5): 449-456, sept.-oct. 2019. tab, graf
Artigo em Inglês | IBECS | ID: ibc-186519

RESUMO

Background: Limited studies conducted on children <2 years old and/or involving a skin prick test (SPT) for fresh milk (FM) have examined the predictive value of allergometric tests for outgrowth of cow's milk allergy (CMA). We investigated the optimal decision points for outgrowth (ODPfo) with SPT for commercial cow's milk extract (CE) and FM and specific immunoglobulin E (sIgE) levels for milk proteins to predict outgrowing allergy in children < 2 years old. Methods: SPTs for CE and FM, tests for sIgEs (cow's milk, casein, alfa-lactoalbumin, Beta-lactoglobulin) and oral food challenges (OFC) were performed in children referred for evaluation of suspected CMA, and 15 months after diagnosis. Results: Fifty-one children (median age, 7.5 months; range, 2-23 months) were enrolled. Five had a history of anaphylaxis and 26 of 48 children with a positive initial challenge underwent milk elimination. The last OFC was performed in 28 children of whom 13 reacted to milk. The initial SPT responses to CE and FM and milk sIgE levels of the patients with persistent CMA were higher at diagnosis, with ODPfo of 7 mm, 9 mm, and 10.5 kU/L, respectively; these values remained higher with ODPfo of 4 mm, 11 mm, and 10.5 kU/L at the last OFC. Conclusion: Higher initial SPTs for FM and CE and higher initial sIgE levels for cow's milk proteins are associated with a reduced likelihood of outgrowth. Initial milk sIgE level < 10.5 kU/L and initial SPT for fresh milk < 9mm are related to the acquisition of tolerance in the follow-up period


No disponible


Assuntos
Humanos , Animais , Masculino , Feminino , Lactente , Gatos , Alérgenos/imunologia , Testes Diagnósticos de Rotina/métodos , Imunoglobulina E/metabolismo , Hipersensibilidade a Leite/diagnóstico , Proteínas do Leite/imunologia , Tomada de Decisão Clínica , Tolerância Imunológica , Prognóstico , Testes Cutâneos
20.
Allergol. immunopatol ; 47(4): 322-327, jul.-ago. 2019. tab
Artigo em Inglês | IBECS | ID: ibc-186502

RESUMO

Background: Children with IgE-mediated cow's milk allergy (IgE-CMA) with gastrointestinal symptoms tolerate yogurt at 100%. Yogurt tolerance in children with IgE-CMA with urticaria and anaphylaxis was 7%. Methods: We enrolled children with IgE-CMA with cutaneous, respiratory, gastrointestinal and anaphylactic symptoms. All performed prick by prick (PbP) and oral food challenge (OFC) with yogurt. Some children performed also an OFC with CM mixed with wheat flour and baked, baked liquid CM, parmesan. Results: 34 children were enrolled, 31/34 (91%) with systemic adverse reaction after ingestion of CM (systemic CMA), 3/34 (9%) with isolated contact urticaria (ICU CMA). PbP with yogurt was negative only in one patient. OFC with yogurt was passed (that is, the OFC was negative) by 20/31 (64%) of the children with systemic CMA. 10/11 (91%) of the patients who failed OFC (that is, the OFC was positive) with yogurt were positive to SPT with casein vs. 8/20 (40%) of the patients who passed it (p = 0.018). None of the 19 children who passed OFC with yogurt failed all OFC with processed CM forms other than yogurt that tested vs. 4/8 among those who failed OFC with yogurt (p = 0.006). The rub test with yogurt was negative in 1/3 (33%) of the patients with ICU CMA. Conclusions: The results of our study are placed alongside others already present in the literature and concerning other methods of processing CM proteins and help to reduce the dietary restrictions of the majority of children with systemic IgE-CMA


No disponible


Assuntos
Humanos , Animais , Masculino , Feminino , Lactente , Pré-Escolar , Gatos , Imunoglobulina E/metabolismo , Hipersensibilidade a Leite/imunologia , Iogurte , Administração Oral , Alérgenos/imunologia , Caseínas/imunologia , Tolerância Imunológica , Testes Cutâneos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...